The Staying Safe Intervention

Status unconfirmed · Not applicable

Conditions studied: Hepatitis C, Opioid Use

In brief

The growing population of young people who inject drugs (PWID) is at extremely high risk for HCV infection through the use of contaminated injection equipment, yet, to date, no behavioral intervention has been sufficiently potent to produce significant reductions in HCV incidence among PWID. To address this critical public health need, our team developed Staying Safe (Ssafe), an innovative, strengths-based, socio-behavioral HCV prevention intervention found in preliminary research to be highly acceptable and feasible, with strong indications of efficacy. The proposed randomized, controlled trial will assess the effectiveness of the Ssafe intervention in reducing both injection-related HCV/HIV risk behavior and HCV incidence among young adults (ages 18-29) who inject opioids (heroin and/or prescription opioids).

Key facts

Study ID

NCT03418636

Run by

National Development and Research Institutes, Inc.

People needed

456

Starts

2018-01-31

Expected to finish

2021-05-31

Last updated by the study team

2018-05-15

Who can join

Age: 18 and older, up to 29. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hepatitis C antibody-negative
• HIV antibody-negative
• Have injected drugs 4 or more times in the past 30 days
• Current opioid use (verified by rapid urine screen)
• Speak English
• Willing to participate in assigned intervention

Where it is running

• Staying Safe Study 235 Eldridge Street — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.